$400M Private Placement at 52-Week Low Threatens Massive Dilution
ENLV is trading near its 52-week low of $4.02 (14% below the low).
Summary
Enlivex has entered a securities purchase agreement for a $400 million private placement with a single institutional investor. At the current $3.47 share price — near the 52-week low and post the 1-for-15 reverse split — this implies roughly 115 million new shares, more than five times the existing float of about 20.7 million shares. The dilution is extreme and will drastically reduce existing shareholders' ownership. The company's market cap is only $72 million, yet it holds a $1.1 billion RAIN token treasury; raising equity at these levels suggests either urgent cash needs or a strategic shift. This follows a series of high-profile announcements around the RAIN token and Allocetra clinical progress, but the financing terms overshadow those positives. Investors should brace for a significant stock price decline when the market opens.
At the time of this announcement, ENLV was trading at $3.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $71.7M. The 52-week trading range was $4.02 to $31.50. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.